Literature DB >> 33493625

Viewpoint | European COVID-19 exit strategy for people with severe mental disorders: Too little, but not yet too late.

Livia J De Picker1, Robert Yolken2, Francesco Benedetti3, Alessandra Borsini4, Igor Branchi5, Paolo Fusar-Poli6, Juan Carlos Leza7, Carmine Pariante8, Thomas Pollak9, Ryad Tamouza10, Benedetta Vai11, Anthony C Vernon12, Michael E Benros13, Marion Leboyer14.   

Abstract

Entities:  

Keywords:  COVID-19; Immunopsychiatry; Mental disorders; SARS-CoV-2; Vaccine

Year:  2021        PMID： 33493625     DOI： 10.1016/j.bbi.2021.01.008

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN： 0889-1591            Impact factor:   7.217


× No keyword cloud information.
  7 in total

1.  Proposed protocol for the investigation of the safety and efficacy of the COVID-19 vaccine for patients with psychosis, with pilot safety findings from a Chinese psychiatrist's self-experiment.

Authors:  Chongguang Lin; Tao Fang; Jiayue Chen; Qianchen Li; Weiliang Yang; Cong Yao; Lina Wang; Yun Sun; Ziyao Cai; Jing Ping; Ce Chen; Langlang Cheng; Jinjing Zhu; Guangdong Chen; Peiwei Shan; Chunmian Chen; Xiaodong Lin; Hongjun Tian; Chuanjun Zhuo
Journal:  Am J Transl Res       Date:  2022-03-15       Impact factor: 4.060

2.  Severe mental illness and European COVID-19 vaccination strategies.

Authors:  Livia J De Picker; Marisa Casanova Dias; Michael E Benros; Benedetta Vai; Igor Branchi; Francesco Benedetti; Alessandra Borsini; Juan Carlos Leza; Hilkka Kärkkäinen; Miia Männikkö; Carmine M Pariante; Ekin Sönmez Güngör; Anna Szczegielniak; Ryad Tamouza; Afra van der Markt; Paolo Fusar-Poli; Julian Beezhold; Marion Leboyer
Journal:  Lancet Psychiatry       Date:  2021-02-17       Impact factor: 27.083

3.  COVID-19-Related Mortality Risk in People With Severe Mental Illness: A Systematic and Critical Review.

Authors:  Marc De Hert; Victor Mazereel; Marc Stroobants; Livia De Picker; Kristof Van Assche; Johan Detraux
Journal:  Front Psychiatry       Date:  2022-01-13       Impact factor: 4.157

4.  Riboflavin for COVID-19 Adjuvant Treatment in Patients With Mental Health Disorders: Observational Study.

Authors:  R A Akasov; E V Khaydukov; D S Andreyuk; N V Sholina; A N Sheremeta; D V Romanov; G P Kostyuk; V Ya Panchenko; M V Kovalchuk
Journal:  Front Pharmacol       Date:  2022-03-10       Impact factor: 5.810

Review 5.  Joint European policy on the COVID-19 risks for people with mental disorders: An umbrella review and evidence- and consensus-based recommendations for mental and public health.

Authors:  Benedetta Vai; Mario Gennaro Mazza; Casanova Dias Marisa; Julian Beezhold; Hilkka Kärkkäinen; John Saunders; Jerzy Samochowiec; Francesco Benedetti; Marion Leboyer; Paolo Fusar-Poli; Livia De Picker
Journal:  Eur Psychiatry       Date:  2022-08-16       Impact factor: 7.156

6.  Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis.

Authors:  Benedetta Vai; Mario Gennaro Mazza; Claudia Delli Colli; Marianne Foiselle; Bennett Allen; Francesco Benedetti; Alessandra Borsini; Marisa Casanova Dias; Ryad Tamouza; Marion Leboyer; Michael E Benros; Igor Branchi; Paolo Fusar-Poli; Livia J De Picker
Journal:  Lancet Psychiatry       Date:  2021-07-15       Impact factor: 27.083

7.  A Pilot Study on Covid and Autism: Prevalence, Clinical Presentation and Vaccine Side Effects.

Authors:  Natascia Brondino; Federico Bertoglio; Federico Forneris; Silvia Faravelli; Alessandro Borghesi; Stefano Damiani; Umberto Provenzani; Marta Nola; Miriam Olivola; Monica Caviglia; Pierluigi Politi; Laura Fusar-Poli; Paolo Fusar-Poli
Journal:  Brain Sci       Date:  2021-06-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.